Artivion Reports Strong Revenue Growth Amid Widening Net Losses
Artivion Inc. (NYSE:AORT) reported a second-quarter revenue increase of $125.8 million, up 11% year-over-year on a GAAP basis, driven by strong performance in its On-X and stent graft product lines. The company also completed the acquisition of Endospan Ltd. and received FDA approval for its AMDS Hybrid Prosthesis, enhancing its position as having one of the most comprehensive aortic arch portfolios globally. Despite these achievements, Artivion posted a net loss of $13.5 million in Q2 2026 compared to a profit of $1.3 million during the same period last year. Non-GAAP net income also declined from $10.7 million to $6.3 million. The losses are attributed to integration costs, foreign currency revaluation impacts, and ongoing expenses related to its recent acquisition. The company reiterated full-year revenue guidance of between $480 million and $496 million but has not raised it despite hitting key milestones in 2026. Institutional ownership dipped slightly as hedge funds reduced their holdings from 28 to 24, while short interest remains at a notable level.
Tickers: $AORT